Legal wrangle over cheaper treatment for Macular Degeneration
Monday 11 December 2017A dozen Clinical Commissioning Groups (CCGs) are poised to lock horns with leading pharmaceutical companies over the right to offer a less expensive drug for the treatment of Macular Degeneration. The bone of contention is the whether Avastin – a drug licensed by the European Medicines Agency (EMA) but not specifically to treat AMD – should be offered to patients as an alternative to Lucentis and Eylea.
The cost implications are enormous: Avastin costs £70 per injection, but Lucentis is over £700. Pharmaceutical firms Bayer (Eylea) and Novartis (Lucentis) are threatening legal action if the CCGs offer Avastin. claiming that prescribing it “undermines guidelines” set out by the General Medical Council and the National Institute for Clinical Excellence.
The 12 CCGs claim that clinical trials have shown Avastin to be suitable, and that offering it could save them up to £13.5m a year within five years. It has been estimated that the NHS as a whole could save £500m a year. In a time of necessary cost cutting, the outcome of this dispute could herald a landmark shift in the relationship between CCGs, the GMC and pharmaceutical companies.
Sources:
Subscribe to our email newsletter and claim your FREE copy of our popular guide '9 Top Tips to Save Your Sight'
Comments
Post a comment…
A Serious Blog
News and views from around the world on lighting, eyecare and eye conditions.
Twitter: @seriousreaders
Facebook:facebook.com/seriousreaders
Recent posts
- Spring forward: Your guide to the 2024 British Summer Time shift
- A spark of genius - the history of the light bulb
- A worded world: Celebrating the Oxford English Dictionary's legacy
- High street cataract and glaucoma tests to reduce NHS waiting lists?
- Eye health resolutions for 2024: your comprehensive guide to preserving and enhancing eyesight
Browse by label
- AMD
- AMD Sight News
- Blue Light
- Cataracts
- Diabetic Retinopathy
- Glaucoma
- Glaucoma Sight News
- Light News
- Light News Glaucoma Sight News
- Light News Sight News
- Literary Festivals
- Literary Festivals Literary News
- Literary News
- OCT Scans: A New Tool In Multiple Sclerosis Diagnosis
- Serious News
- Sight News
- Sight News AMD
- Sight News Blue Light
- Sight News Cataracts
- Sight News Glaucoma
Wholeheartedly supporting this drive for acceptable alternative. In particular as I lost sight on my left eye which was removed completely at age 9 and therefore have to rely on my good right eye alone.